Abstract
Triple antimalarial combination therapies combine potent and rapidly cleared artemisinins or related synthetic ozonides, such as arterolane, with two, more slowly eliminated partner drugs to reduce the risk of resistance. We aimed to assess the safety, tolerability, and efficacy of arterolane-piperaquine-mefloquine versus arterolane-piperaquine and artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in Kenyan children. In this single-centre, open-label, randomised, non-inferiority trial done in Kilifi County Hospital, Kilifi, coastal Kenya, children with uncomplicated Plasmodium falciparum malaria were recruited. Eligible patients were aged 2-12 years and had an asexual parasitaemia of 5000-250 000 parasites per μL. The exclusion criteria included the presence of an acute illness other than malaria, the inability to tolerate oral medications, treatment with an artemisinin derivative in the previous 7 days, a known hypersensitivity or contraindication to any of the study drugs, and a QT interval corrected for heart rate (QTc interval) longer than 450 ms. Patients were randomly assigned (1:1:1), by use of blocks of six, nine, and 12, and opaque, sealed, and sequentially numbered envelopes, to receive eit...Continue Reading
References
Feb 16, 2000·Transactions of the Royal Society of Tropical Medicine and Hygiene·G SnounouS Viriyakosol
Jul 19, 2002·Nature·John C WoottonXin-Zhuan Su
Aug 25, 2004·Science·Cally RoperTim Anderson
Apr 20, 2005·Transactions of the Royal Society of Tropical Medicine and Hygiene·Catherine FaladePatricia Ibarra de Palacios
Feb 16, 2007·Tropical Medicine & International Health : TM & IH·Elizabeth A AshleyFrançois Nosten
Sep 14, 2010·The Lancet Infectious Diseases·Frank SmithuisNicholas J White
Nov 15, 2011·Malaria Journal·Jennifer A FleggKasia Stepniewska
Jul 23, 2014·The American Journal of Tropical Medicine and Hygiene·Meera Venkatesan Asaq Molecular Marker Study Group
Jul 31, 2014·The New England Journal of Medicine·Elizabeth A AshleyUNKNOWN Tracking Resistance to Artemisinin Collaboration (TRAC)
Sep 17, 2015·Nature·S BhattP W Gething
Jan 29, 2016·Malaria Journal·Neena ValechaAnupkumar R Anvikar
Feb 26, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Offianan Andre TourePaul Swoboda
May 11, 2016·Antimicrobial Agents and Chemotherapy·Tuo YangLeann Tilley
May 18, 2016·Nature Communications·M Isabel VeigaDavid A Fidock
Jun 18, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Aung Pyae PhyoFrancois Nosten
Nov 8, 2016·The Lancet Infectious Diseases·Roberto AmatoRick M Fairhurst
Apr 13, 2017·MBio·Judith StraimerDavid A Fidock
Jan 20, 2018·BMC Medicine·W Robert TaylorMavuto Mukaka
May 4, 2018·Nature Communications·Selina BoppSarah K Volkman
Jun 12, 2018·The Lancet Infectious Diseases·Xin Hui S ChanNicholas J White
Mar 25, 2019·Malaria Journal·Edwin G TseMatthew H Todd
Jun 10, 2019·Trends in Parasitology·Carlo GiannangeloDarren J Creek
Jun 12, 2019·Antimicrobial Agents and Chemotherapy·Borimas HanboonkunupakarnPodjanee Jittamala
Jul 28, 2019·The Lancet Infectious Diseases·Rob W van der PluijmArjen M Dondorp
Mar 15, 2020·Lancet·Rob W van der PluijmUNKNOWN Tracking Resistance to Artemisinin Collaboration
Aug 5, 2020·Nature Medicine·Aline UwimanaDidier Menard